BioMarin Pharma (BMRN) Tops Q4 EPS by 31c
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
EPS Growth %: -34.0%
Financial Fact:
NET INCOME (LOSS) PER SHARE, DILUTED: -0.26
Today's EPS Names:
JFIN, KEQU, LASE, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q4 EPS of $0.12, $0.31 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $452.1 million versus the consensus estimate of $440.23 million.
GUIDANCE:
BioMarin Pharma sees FY2021 revenue of $1.75-1.85 billion, versus the consensus of $1.91 billion.
Item | 2021 Guidance * | ||||||
Total Revenues | $1,750 | to | $1,850 | ||||
Vimizim Net Product Revenues | $570 | to | $610 | ||||
Kuvan Net Product Revenues | $250 | to | $290 | ||||
Naglazyme Net Product Revenues | $365 | to | $395 | ||||
Palynziq Net Product Revenues | $210 | to | $250 | ||||
Brineura Net Product Revenues | $120 | to | $140 | ||||
Cost of Sales (% of Total Revenues) | 23% | to | 25% | ||||
Research and Development Expense | $645 | to | $695 | ||||
Selling, General and Administrative Expense | $725 | to | $775 | ||||
GAAP Net Loss | ($130) | to | ($80) | ||||
Non-GAAP Income (1) | $170 | to | $220 | ||||
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- OneMain (OMF) Reiterated at Market Outperform by Citizens on Updated Estimates
- JPMorgan Starts ICICI Prudential Asset Management (ICICIAMC:IN) at Overweight
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
